
Updated trial data showed responses across two treatment lines, with low rates of treatment discontinuation and no treatment-related deaths.
Genmab reported Phase 2 data showing response rates of 75% in first-line and 67% in second-line treatment when petosemtamab was combined with chemotherapy for metastatic colorectal cancer. The company presented the updated results at the European Society for Medical Oncology congress in Madrid.
The analysis covered 79 treated patients. Median follow-up was 5.9 months in the first-line group and 7.1 months in the second-line group. Disease control rates exceeded 93%, according to the report.
Treatment discontinuations due to adverse events ranged from 3% to 5%, and no treatment-related deaths were reported. Genmab said the data support its ongoing Phase 3 LiGeR program.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.